Sign In
Buy MDGEF
$2.59
+0 (+0%)
At Close: Jun 03, 2026
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
05:00am, Wednesday, 19'th Feb 2025
Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapi
Medigene AG announces closing of its first SEPA tranche
12:00pm, Monday, 03'rd Feb 2025
Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
05:00am, Monday, 09'th Dec 2024
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
05:00am, Tuesday, 03'rd Dec 2024
Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
03:00am, Wednesday, 25'th Sep 2024
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell recep
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
05:00am, Thursday, 29'th Aug 2024
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (T
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
05:00am, Monday, 26'th Aug 2024
Number of shares issued decreases from 29,475,189 to 14,737,594 due consolidation of the shares at a ratio of 2:1 Consolidation of shares to take place on August 29, 2024 Planegg/Martinsried, August 2
Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript
01:33pm, Wednesday, 14'th Aug 2024
Medigene AG (OTCPK:MDGEF) Q2 2024 Earnings Conference Call August 14, 2024 9:30 AM ET Company Participants Pamela Keck - Head, IR Selwyn Ho - CEO Conference Call Participants Joe Pantginis - H.C. Wain
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
01:30am, Wednesday, 14'th Aug 2024
Significant corporate and scientific progress in the first half of 2024 Advancement of lead program MDG1015 with IND filing on track for 3Q 2024 and CTA filing for 4Q 2024 New additions to End-to-End
Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
10:15am, Thursday, 08'th Aug 2024
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TC
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
04:00am, Thursday, 08'th Aug 2024
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispeci
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
04:00am, Thursday, 08'th Aug 2024
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design an
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
05:00am, Wednesday, 03'rd Jul 2024
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immun
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell i
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
04:00am, Tuesday, 21'st May 2024
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiat
